NCT00003432View on ClinicalTrials.gov

Immunotherapy in Treating Patients With Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

June 30, 1998

Primary Completion Date

November 30, 2002

Study Completion Date

November 30, 2002

Conditions
Breast Cancer
Interventions
BIOLOGICAL

carcinoembryonic antigen RNA-pulsed DC cancer vaccine

Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER